Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $2.2 million.

  • Medifast's Share-based Compensation rose 187.62% to $2.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 million, marking a year-over-year increase of 374.85%. This contributed to the annual value of $7.6 million for FY2025, which is 374.85% up from last year.
  • As of Q4 2025, Medifast's Share-based Compensation stood at $2.2 million, which was up 187.62% from $910000.0 recorded in Q3 2025.
  • Medifast's 5-year Share-based Compensation high stood at $3.3 million for Q4 2021, and its period low was $606000.0 during Q1 2023.
  • In the last 5 years, Medifast's Share-based Compensation had a median value of $2.3 million in 2021 and averaged $2.2 million.
  • Data for Medifast's Share-based Compensation shows a peak YoY increase of 25825.08% (in 2024) and a maximum YoY decrease of 7734.58% (in 2024) over the last 5 years.
  • Over the past 5 years, Medifast's Share-based Compensation (Quarter) stood at $3.3 million in 2021, then dropped by 10.33% to $2.9 million in 2022, then dropped by 18.88% to $2.4 million in 2023, then fell by 10.91% to $2.1 million in 2024, then increased by 1.88% to $2.2 million in 2025.
  • Its Share-based Compensation stands at $2.2 million for Q4 2025, versus $910000.0 for Q3 2025 and $2.6 million for Q2 2025.